key: cord-0947269-161jsyuf
authors: Brown, Alison E.; Croxford, Sara E.; Nash, Sophie; Khawam, Jameel; Kirwan, Peter; Kall, Meaghan; Bradshaw, Daniel; Sabin, Caroline; Miller, Robert F.; Post, Frank A.; Harding, Richard; Collins, Simon; Waters, Laura; Asboe, David; Chadwick, David R.; Delpech, Valerie; Sullivan, Ann K.
title: COVID‐19 mortality among people with diagnosed HIV compared to those without during the first wave of the COVID‐19 pandemic in England
date: 2021-09-15
journal: HIV Med
DOI: 10.1111/hiv.13167
sha: 641e1e0cb080201bfcb799c82a8e8d627367cd28
doc_id: 947269
cord_uid: 161jsyuf

OBJECTIVES: We describe COVID‐19 mortality among people with and without HIV during the first wave of the pandemic in England. METHODS: National surveillance data on adults (aged ≥ 15 years) with diagnosed HIV resident in England were linked to national COVID‐19 mortality surveillance data (2 March 2020–16 June 2020); HIV clinicians verified linked cases and provided information on the circumstances of death. We present COVID‐19 mortality rates by HIV status, using negative binomial regression to assess the association between HIV and mortality, adjusting for gender, age and ethnicity. RESULTS: Overall, 99 people with HIV, including 61 of black ethnicity, died of/with COVID‐19 (107/100 000) compared with 49 483 people without HIV (109/100 000). Compared to people without HIV, higher COVID‐19 mortality rates were observed in people with HIV of black (188 vs. 122/100 000) and Asian (131 vs. 77.0/100 000) ethnicity, and in both younger (15–59 years: 58.3 vs. 10.2/100 000) and older (≥ 60 years: 434 vs. 355/100 000) people. After adjustment for demographic factors, people with HIV had a higher COVID‐19 mortality risk than those without (2.18; 95% CI: 1.76–2.70). Most people with HIV who died of/with COVID‐19 had suppressed HIV viraemia (91%) and at least one comorbidity reported to be associated with poor COVID‐19 outcomes (87%). CONCLUSIONS: In the first wave of the pandemic in England, COVID‐19 mortality among people with HIV was low, but was higher than in those without HIV, after controlling for demographic factors. This supports the strategy of prioritizing COVID‐19 vaccination for people with HIV and strongly encouraging its uptake, especially in those of black and Asian ethnicity.

Reliable ascertainment and description of mortality are critical in informing the public health response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which can lead to coronavirus disease . Examining the disparities in outcomes between population subgroups provides critical insight into which are the most severely affected, enabling the development of specific health policies to protect these populations.

In England, an estimated 96 200 people live with HIV, with 6% unaware of their infection [1] . Of those diagnosed, 98% receive antiretroviral treatment (ART) and of those on treatment, 97% are virally suppressed; this is equivalent to at least 89% of all people living with HIV in England having an undetectable viral load [1] . Although ART is effective in restoring immunity and uptake is high [2] , persistent immune dysfunction and chronic inflammation may put people with HIV at increased risk of COVID-19 mortality due to a reduced ability to mount a protective immune response. Additionally, in England, people with HIV are more likely to be male and belong to communities known to experience socioeconomic deprivation, both of which are predictors of adverse COVID-19 outcomes [3, 4] . Evidence on the risk of death from COVID-19 among people with HIV versus the general population is mixed, with some studies suggesting higher mortality rates [5] [6] [7] [8] but others reporting little difference in mortality [9] [10] [11] .

We use comprehensive national surveillance data to provide an epidemiological description of COVID-19 mortality among all people with diagnosed HIV during the first wave of the COVID-19 pandemic in England and compare the mortality burden to people without HIV.

People with HIV As part of the national HIV surveillance programme, clinical and epidemiological information on all adults (aged ≥ 15 years) accessing HIV care in England is submitted to the HIV and AIDS Reporting System (HARS) at Public Health England (PHE) by National Health Service (NHS) specialist outpatient clinics [12] . Individual follow-up begins at diagnosis; data collected for each subsequent attendance for HIV outpatient care include: CD4 count (where indicated), HIV treatment status, HIV viral load and the presence of AIDS-defining illnesses.

Information on deaths among people with HIV (date and cause of death) are reported through routine surveillance, as well as through matching to mortality data from the Office for National Statistics (ONS). In 2019, PHE introduced enhanced surveillance of deaths among people with HIV (Annual National HIV Mortality Review) in collaboration with the British HIV Association (BHIVA) [13] . Briefly, HIV clinicians complete an online modified Causes of Death in HIV [14] reporting form for all deaths among their patients, which captures information on HIV clinical profile, comorbidities, lifestyle risk factors, causes of death and end-of-life care. Data are usually submitted annually and retrospectively. However, to better understand the impact of COVID-19 on people with HIV, rates were observed in people with HIV of black (188 vs. 122/100 000) and Asian (131 vs. 77.0/100 000) ethnicity, and in both younger (15- reported to be associated with poor COVID-19 outcomes (87%).

In the first wave of the pandemic in England, COVID-19 mortality among people with HIV was low, but was higher than in those without HIV, after controlling for demographic factors. This supports the strategy of prioritizing COVID-19 vaccination for people with HIV and strongly encouraging its uptake, especially in those of black and Asian ethnicity.

adults, COVID-19, England, HIV, mortality clinicians were contacted through the BHIVA network and asked to submit a mortality review form following each death of/with COVID-19 in a person with HIV.

In England, COVID-19 deaths in the general population are reported to PHE daily through four sources: (1) the COVID-19 Patient Notification System (hospital deaths) [15] ; (2) [16] to ascertain cause and place of death, and to Hospital Episode Statistics to identify ethnicity, and linkage to area-level data on socioeconomic status [index of multiple deprivation (IMD)] [17] . In England, COVID-19 was first detected on 30 January 2020, with the first death of/with COVID-19 occurring on 2 March 2020 [18] .

The general population COVID-19 mortality dataset (data to 16 June 2020) was linked to the national HIV surveillance dataset using a combination of pseudo-anonymized identifiers [Soundex (scrambled surname) [19] , first initial, date of birth, gender and lower super output area of residence] (PHE Caldicott approval: NISCRP552020). Two epidemiologists reviewed all matches independently, with disparities reviewed by an HIV clinician and consensus agreed. For matches deemed to be definite (exact matches for all information) or probable (matches for most information), clinicians were contacted by PHE and asked to confirm that the HIV patient had died and to submit the mortality review form ( Figure S1 ). Where clinical information collected through the mortality review form conflicted with that collected in HARS (e.g. ART start date), the clinician-reported data were prioritized. For the five people with no mortality review form completed, HARS clinical profile data were used, where available.

People were considered to have died of/with COVID-19 if their death occurred within 60 days of a positive COVID-19 test [either polymerase chain reaction (PCR) (majority), nucleic acid amplification test (NAAT) or serological], with COVID-19 included on the ONS death registration form (death certificate), or if COVID-19 was reported as a cause of death by the reporting clinician.

We present a descriptive analysis of adults with and without HIV resident in England who died of/with COVID-19 between 2 March and 16 June 2020 (3.5 months). There were no deaths reported among children aged < 15 years with HIV over this time period.

Crude mortality rates were calculated as the number of COVID-19 deaths per 100 000 population for those with and without HIV, comparing those aged 15-59 years with those aged ≥ 60. [20] . Latest available mid-year ONS population estimates were used: 2019 for IMD and region of residence and 2017 for ethnicity. Data were available by gender, age at death (5-year age bands) and ethnicity, region or IMD.

Multivariable negative binomial regression was used to assess the association between HIV and death of/with COVID-19, adjusting firstly for age at death and subsequently for gender, age at death and ethnicity. Interaction terms were added to assess effect modification by age and ethnicity. Separate models were built to describe associations between mortality and region of residence and IMD, adjusting for gender, age at death and HIV status.

We also describe the clinical profile of people with HIV who died of/with COVID-19 overall and by gender, age and ethnicity. Comorbidities reported to increase the risk of COVID-19 death include: cardiovascular disease (CVD) (including hypertension), diabetes mellitus, chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), obesity and dementia/cognitive impairment [21] . Detailed information on comorbidities was available for those people with a completed mortality review form (n = 94); for the remainder, information on comorbidities was taken from the death certificate. Viral suppression was defined as a viral load of < 200 copies/mL. HIV viral load and CD4 count measurements were considered to be 'at death' if within a year of death.

All analyses were carried out using Stata v.15.0 (Stata Corp, College Station, TX, USA).

As of 16 June 2020, there were 99 COVID-19 deaths reported among the 92 643 adults with diagnosed HIV in England, equivalent to a crude mortality rate of 107/100 000 population (Table 1 ). In comparison, there were 49 483 COVID-19 deaths reported among the 45 565 024 people without HIV over the same period, equivalent to a crude rate of 109/100 000.

Overall, the median age of death among people with HIV who died of/with COVID-19 was 60 years [interquartile range (IQR): 51-72], with 53% (52/99) aged ≥ 60. By comparison, median age of death among people without HIV who died with/of COVID-19 was 83 years (IQR: 74-89), with 93% (46 195/49 483) aged ≥ 60. Sixty-nine percent (n = 68) of all COVID-19 deaths in people with HIV were among men, compared with 55% (n = 27 204) of those among people without HIV (Table 1 ). These differences largely reflect variation in the structure of the populations, whereby 13% (11 974/92 643) of all people with HIV were aged ≥ 60 and 69% (n = 63 585) were men compared with 29% (13 016 372/45 565 024) and 49% (n = 22 539 107) of those without HIV, respectively. Figure S2 shows the age and sex structure of both populations compared with the age and sex structure of those who died of/with COVID-19 and of any cause.

Higher crude mortality rates were observed among people aged ≥ 60 than among younger individuals (434 vs. 58.3/100 000 among people with HIV and 355 vs. 10.1/100 000 among those without) ( 

After adjustment, the risk of COVID-19 death was 2.18 [95% confidence interval (CI): 1.76-2.70] times higher in people with HIV than in those without ( describing the association between region of residence and IMD on mortality can be found in Table S1 . The median time between HIV diagnosis and COVID-19-related death was 15 years (IQR: [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] ; three people died within 3 months of their HIV diagnosis and five within 1 year (Table 3 ). Access to outpatient specialist HIV care was high, with 95% (n = 94) attending at least once since their HIV diagnosis. Among those who accessed HIV care, 94% (n = 88) were last seen between 2018 and 2020, 5% (n = 5) were last seen between 2016 and 2017 and one person was last seen in 2002. The coverage of ART was 99% (n = 98) overall, with 94% (89/95) documented as receiving ART at death or in the preceding year [median time since ART initiation: 14 years (IQR: [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] ]. Of the 69 people with a CD4 count reported in the year prior to death, 1.4% (n = 1), 16% (n = 11) and 42% (n = 29) had a CD4 count < 50, < 200 and < 350 cells/µL, respectively. Of those with a CD4 < 350 cells/ µL, all were aged ≥ 40 years, 83% (n = 24) were ≥ 50 years old and 62% (n = 18) were ≥ 60. Of the 92 people with any CD4 count available, 14% (n = 13), 53% (n = 49) and 86% (n = 79) had a CD4 nadir < 50, < 200 and < 350 cells/µL, respectively. Overall, 91% (83/91) of people were virally suppressed. There were no significant differences by gender or ethnicity with regard to HIV clinical markers and ART uptake.

Ninety per cent (89/99) of people with HIV who died had at least one reported comorbidity; 87% (n = 82) had at least one documented comorbidity known to be associated with higher risk of poor COVID-19 outcomes (65% at least two) [21] . The prevalence of specific comorbidities was as follows: CVD (including hypertension), 69% (57/83); diabetes mellitus, 48% (40/83); CKD, 41% (32/78); COPD, 10% (8/77); and dementia/cognitive impairment, 17% (9/51). Among those with height and weight available (n = 70), 49% (n = 34) had a body mass index (BMI) of >30 kg/m 2 indicating obesity, and a further 26% (n = 18) were overweight (BMI 25-30 kg/m 2 ). While diabetes mellitus was more common in men, obesity and dementia/cognitive impairment were more common in women. Diabetes mellitus, CVD, CKD and obesity were 

more common among people of black ethnicity than among those of white ethnicity (Table 3) . Table 4 presents the burden of comorbidities known to be associated with poor COVID-19 outcomes among people with diagnosed HIV who died of/with COVID-19 by gender, age at death and ethnicity. Of the 47 people who died aged < 60, 74% had at least one documented comorbidity associated with poor COVID-19 outcomes; 55% had two or more comorbidities and 19% had one. This compares with 96% among the 25 people who died age 60-69 years (80% had two or more comorbidities and 16% had one) and 85% among the 27 people who died aged ≥ 70 (70% had two or more and 15% had one). Among the 12 people aged < 60 years with no documented comorbidities, three were not virally suppressed within a year of death. The prevalence of comorbidities was high for both men and women, and across ethnicities.

We describe COVID-19 mortality among people with diagnosed HIV during the first wave of the pandemic in England. The overall mortality rate due to COVID-19 among people with HIV was low, at approximately 0.1%. Whilst this low death rate is reassuring, it is possible that a relatively small proportion of the population (particularly those with HIV) was exposed to the virus during the first 3.5 months of the pandemic [22] . United Kingdom government advice to 'stay at home' and 'socially distance' was released in March and specific groups of the population, identified as clinically extremely vulnerable, were asked to 'shield' by staying home for 3 months and avoid all non-household contacts [23] . People with HIV were initially included in the government's shielding advice; however this was subsequently changed in line with advice issued by BHIVA in late April recommending that only individuals with CD4 counts < 50 cells/µL, a recent AIDS diagnosis and/or multiple comorbidities should 'shield' [24] . Consequently, the risk of death among those most clinically vulnerable with HIV may be underestimated in our study.

Although mortality was low overall, COVID-19 mortality among people with HIV in England was more than double that of people without HIV after differences in the population age structure were taken into consideration. This is consistent with other published studies [5] [6] [7] [8] . Primary care data from the OpenSAFELY platform showed people living with HIV had higher risk of COVID-19 death (hazard ratio = 2.90, 95% CI: 1.96-4.30) than those without HIV after adjusting for age and sex [5] . The ISARIC study of a subset of patients hospitalized with COVID-19 in the UK found a 63% increased risk of mortality among those with HIV compared with HIV-negative individuals after adjusting for sex, ethnicity, age, baseline date, comorbidities and disease severity at presentation [8] . Similar to these other studies, our findings should be interpreted with caution [25] . Unlike OpenSAFELY and ISARIC, which were restricted to analysis of specific subgroups (e.g. people registered at general practice or in hospital), we utilized comprehensive national HIV surveillance data including all people living with diagnosed HIV and had access to data on all people who died of/with COVID-19 in the general population. Nevertheless, we were limited by a lack of available data on comorbidities for those without HIV to adjust our analyses; this is particularly important as people with HIV are known to have higher levels of comorbidities than the general population [3, 26] .

Our analyses show that among people with HIV who died of/with COVID-19, the large majority (88%) were either aged ≥ 60 (53%) or had at least one documented comorbidity known to be a risk factor for COVID-19 death (87%). There were very few deaths among people with diagnosed HIV aged < 60 without a documented comorbidity. The comorbidities commonly reported among people with HIV who died of/with COVID-19 in England included CVD (69%), obesity (49%), diabetes mellitus (48%), CKD (41%) and hypertension (39%). These rates are higher than those reported among all people living with diagnosed HIV (Table S2 ) [3, 26] , higher than those documented among people with HIV who died pre-COVID-19 and higher than the general population as a whole [27, 28] . These findings are consistent with the literature and highlight the importance of ensuring optimal care of comorbidities alongside HIV care [29] [30] [31] [32] .

Over two-thirds of the people with HIV who died of/ with COVID-19 were from black, Asian or ethnic minority populations; only 35% of people living with diagnosed HIV in England are of these ethnicities. We observed a higher risk of COVID-19 mortality in people of an ethnic minority with HIV, compared with those without, remained after adjustment for age and gender. Higher COVID-19 diagnosis rates have been observed among people of black ethnic groups in England than among other ethnic groups, as well as higher mortality rates [21, 33] . This disparity may be partially explained by socioeconomic factors, comorbidities and occupational exposure to COVID-19, with a relatively high proportion of people of black ethnicity employed in health and social care roles [32, 34, 35] . Our ability to characterize the relationship between ethnicity and mortality was limited by a lack of data on underlying COVID-19 testing and diagnosis rates and an inability to adjust for occupational exposure. Furthermore, despite finding that an increased risk of death was seen among those in London and those living in areas of higher deprivation (Table S1 ), we could not adjust for ethnicity, IMD and region of residence in the same model, due to a lack of available general population data. This is the first population-level national study of COVID-19 mortality among people with HIV in the UK, capturing all deaths during the first wave. We linked the national cohort of people diagnosed with HIV to national COVID-19 death data, including people not linked to HIV care and those lost to clinical follow up, groups that may be particularly vulnerable to COVID-19. Additional clinical data were collected on those who died to ascertain the treatment and immunosuppression levels, as well as better understand comorbidities and cause of death. PHE reports to date have focused on people who have died within 28 and 60 days of a positive COVID-19 test or linked to a death registration certificate [36] . We also included deaths where COVID-19 was entered on the death certificate of individuals who were not linkable to a positive COVID-19 test; most of these deaths occurred at the start of the pandemic where testing was not widely available.

However, our study has several additional limitations. Mortality rates among people with HIV presented here exclude deaths among the 5900 people estimated to have undiagnosed infection in England; however, this is a relatively low proportion (6%) among all people with HIV in the country [1] . We are not yet able to calculate excess mortality as surveillance of deaths among people with HIV in 2020 is still under way. We cannot calculate case fatality or account for any differences in exposure to COVID-19 comparing HIV and those without [37] . Despite HIV surveillance being comprehensive and of high quality, there were some missing data which may have affected our findings. Notably, CD4 counts in the year preceding death were only available for 70% of people who died of/with COVID-19; this reflects current UK monitoring guidelines which do not require annual CD4 testing for those with well-controlled HIV [38] . COVID-19 is known to dysregulate the immune system and lower CD4 cell counts [39] ; in our analysis we included at least 17 people with a CD4 measured within 2 weeks of or Information available for those people with a mortality review form completed (n = 94) and the two additional people who had relevant comorbidities listed on the death certificate. c Other ethnicity: Asian and other/mixed. after their COVID-19 diagnosis. However, this should have minimal impact as the distribution of these counts was equitable across CD4 strata (Table 3) . Where clinical information collected through the mortality review form conflicted with that collected in HARS, clinician-reported data were prioritized. However, clinicians may not have been aware of previous clinical history if patients died in hospitals where they did not receive HIV outpatient care. Our analysis includes data until June 2020. In England, COVID-19 deaths remained at low sustained levels through the summer months of 2020 before rising again in late September [18] . Over 65 000 additional COVID-19 deaths in the general population were reported to PHE as of 15 February 2021. However, the age, sex and ethnic profile of people who died has not changed substantially over this period and thus we believe the results presented remain representative and relevant across the pre-vaccination era [18] .

In England, where 94% of people with HIV are diagnosed and on suppressive ART, the rate of COVID-19 mortality in the first wave of the COVID-19 pandemic among people with HIV was low but higher than among those without HIV after controlling for age. Few people with HIV who died of/with COVID-19 were aged < 60 and did not have a documented comorbidity associated with worse outcomes. findings highlight that uptake of vaccination in people with HIV of all ages should be strongly encouraged.

Trends in HIV testing, new diagnoses and people receiving HIV-related care in the United Kingdom: data to the end of

Projected life expectancy of people with HIV according to timing of diagnosis

Positive voices: the national survey of people living with HIV: findings from the 2017 survey. PHE

Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission

HIV infection and COVID-19 death: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform

Features of 20 133 UK patients in hospital with COVID-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study

Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa

Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO clinical characterization protocol (UK): a prospective observational study

COVID-19 and people with HIV infection: outcomes for hospitalized patients in New York City

COVID-19 in patients with HIV: clinical case series

Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study

HIV surveillance systems

Annual National HIV Mortality Review

The coding causes of death in HIV (CoDe) project: initial results and evaluation of methodology

PHE data series on deaths in people with COVID-19: technical summary

Office for National Statistics. Deaths involving COVID-19, England and Wales: deaths occurring in

ommun ity/birth sdeat hsand marri ages/death s/bulle tins/death sinvo lving covid 19eng landa ndwal es/death soccu rring inmar ch2020

Communities and Local Government

Epidemiology of confirmed COVID-19 deaths in adults

Soundex' codes of surnames provide confidentiality and accuracy in a national HIV database

Office for National Statistics

Disparities in the risk and outcomes of COVID-19. PHE

Guidance: Staying alert and safe (social distancing

COVID-19 and shielding: advice for HIV clinicians, GPs and people living with HIV

COVID-19 death in people with HIV: interpret cautiously

Positive voices 2017: data tables. PHE

Mortality and causes of death among HIV patients in London in 2017

Quality and outcomes framework 2019-20: prevalence, achievement and personalised care adjustments -regional and national level

Characteristics, comorbidities, and outcomes in a multicenter registry of patients with HIV and coronavirus disease-19

Disproportionate burden of coronavirus disease 2019 among racial minorities and those in congregate settings among a large cohort of people with HIV

Characteristics and outcomes of COVID-19 in patients with HIV: a multi-center research network study

Analysis of the relationship between pre-existing health conditions, ethnicity and COVID-19. PHE

Hospitalized patients with COVID-19 and human immunodeficiency virus: a case series

Are some ethnic groups more vulnerable to COVID-19 than others. Institute of Fiscal Studies, Nuffield Foundation

Occupation and risk of severe COVID-19: prospective cohort study of 120 075 UK Biobank participants

Weekly coronavirus disease 2019 (COVID-19) surveillance report London. PHE

Interpretation of COVID-19 case fatality risk measures in England

BHIVA guidelines for the routine investigation and monitoring of adult HIV-1-positive individuals (2019 interim update). BHIVA

Dysregulation of immune response in patients With coronavirus 2019 (COVID-19) in Wuhan, China

UK government. COVID-19 vaccination first phase priority groups

We gratefully acknowledge the continuing collaboration of people living with HIV, as well as clinicians, microbiologists, immunologists, public health practitioners, occupational health doctors, nurses and other colleagues who contribute to the surveillance of HIV in the UK. We also acknowledge the hard work of the PHE COVID-19 Epidemiology Cell in pulling together the death data. 

Healthcare, Janssen-Cilag and MSD outside the submitted work. RFM reports personal fees from Gilead Sciences for conference attendance and non-promotional talks outside the submitted work. CS reports funding from Gilead Sciences and Janssen-Cilag for participation in advisory panels and for the preparation of educational materials outside the submitted work. DRC reports funding from Gilead Sciences and ViiV Healthcare for the preparation of educational materials and research grants outside the submitted work. RH reports educational consultancies from Gilead Sciences and ViiV Healthcare outside the submitted work. DA reports advisory fees from Gilead Sciences and Viiv Healthcare outside the submitted work.